Objective: About 5% of pregnant women meet criteria for major depression. No pharmacotherapy is specifically approved for antepartum depression; novel treatment approaches may be welcome. The authors explored the use of morning bright light therapy for antepartum depression.
Method: An open trial of bright light therapy in an A-B-A design was conducted for 3-5 weeks in 16 pregnant patients with major depression. The Hamilton Depression Rating Scale, Seasonal Affective Disorders Version, was administered to assess changes in mood. A follow-up questionnaire was used to assess outcome after delivery.
Results: After 3 weeks of treatment, mean depression ratings improved by 49%. Benefits were seen through 5 weeks of treatment. There was no evidence of adverse effects of light therapy on pregnancy.
Conclusions: These data provide evidence that morning light therapy has an antidepressant effect during pregnancy. A randomized controlled trial is warranted to test this alternative to medication.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.ajp.159.4.666 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Graphene oxide-enhanced photothermal therapy: laser parameter optimization and temperature modeling for hela cancer cell mortality.
Lasers Med Sci
January 2025
Biotechnology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Islamic Republic of Iran.
Photothermal therapy, in which a laser is an effective tool, is a promising method for cancer treatment. Laser parameters, including power, irradiation time, type of laser radiation (continuous or chopped), and the concentration of the photothermal agent, can affect the efficiency of this method. Therefore, this study investigated and compared the effects of different laser parameters on the efficiency of photothermal treatment for cervical cancer, which is the fourth most prevalent cancer in women.
View Article and Find Full Text PDFBiomineralized and metallized small extracellular vesicles encapsulated in hydrogels for mitochondrial-targeted synergistic tumor therapy.
Acta Biomater
January 2025
Research Center for Analytical Sciences, Northeastern University, Shenyang, 110819, P. R. China. Electronic address:
Targeted organelle therapy is a promising therapeutic method for significantly regulating the tumor microenvironment, yet it often lacks effective strategies for leveraging synergistic enhancement effect. Engineered small extracellular vesicles (sEVs) are expected to address this challenge due to their notable advantages in drug delivery, extended circulation time, and intercellular information transmission. Herein, we prepare sEVs with pH and photothermal dual-responsiveness, which are encapsulated with hydrogels for a quadruple-efficient synergistic therapy.
View Article and Find Full Text PDFImproving Quality of Care for Neonatal Hyperbilirubinemia Admissions After Birth Hospitalization.
Hosp Pediatr
January 2025
Medical College of Wisconsin, Milwaukee, Wisconsin.
Background And Objectives: Infants with neonatal hyperbilirubinemia (NH) often require admission after their birth hospitalization for treatment with phototherapy. Our aim was to align local practice with updated national guidelines to promote efficiency and decrease length of stay (LOS) for this patient population by ∼ 10% over a 15-month period using quality improvement methodology.
Methods: Our improvement initiative included infants younger than age 14 days born at more than 35 weeks' gestation admitted to the hospital medicine service with an NH diagnosis.
Rational design of AIEgens through π-bridge engineering for dual-modal photodynamic and photothermal therapy.
Bioorg Med Chem
January 2025
School of Pharmacy, Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Guizhou International Science & Technology Cooperation Base of Medical Optical Theranostics Research, Zunyi Medical University, Zunyi, Guizhou 563003, PR China. Electronic address:
A series of aggregation-induced emission luminogens (AIEgens) with donor-π-acceptor (D-π-A) architecture were rationally designed and synthesized through π-bridge engineering for dual-modal photodynamic and photothermal therapy. The AIEgens (TPT, TFT, and TTT) were constructed using methoxy-substituted tetraphenylene as the electron donor and tricyanofuran as the electron acceptor, connected via different π-bridges (phenyl, furan, or thiophene). These compounds exhibited red-shifted absorption (460-545 nm) and emission (712-720 nm) with remarkable aggregation-induced emission characteristics.
View Article and Find Full Text PDFSynergistic Cancer Photoimmunotherapy by Harnessing Near-Infrared-Activated Nanoparticles Containing Charge Transfer Complexes.
Angew Chem Int Ed Engl
January 2025
The University of Oklahoma, Chemistry and Biochemistry, 101 Stephenson Parkway, 73019, Norman, UNITED STATES OF AMERICA.
Phototherapy - which includes photothermal therapy (PTT) and photodynamic therapy (PDT) - has evoked interest as a promising cancer treatment modality on account of its noninvasiveness, spatiotemporal precision, and minimal side effects. C. Wang et al.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!